The KEYNOTE-028 trial assessed pembrolizumab monotherapy in PD-L1-positive, HR+/HER2− breast cancer patients and reported an ORR of only 12%, suggesting limited single-agent activity in this population [22]. The gene discussed is CD274; the disease is breast cancer.